-
Dr. Etai Adam, MD
- Department: Pediatric Hematology, Oncology and Bone Marrow Transplant
- Specialties: Pediatrics, Pediatric Hemato-Oncology, Pediatric Bone Marrow Transplant
- Language: English, Hebrew
- Request Consultation
About Me
Dr. Etai Adam is pediatric hematologist/oncologist specializing in bone marrow transplant. He completed training in Pediatrics and in Pediatric Hematology/Oncology at Children’s Hospital Los Angeles and has been at Sheba Medical Center since 2017.
His main clinical area of focus is hematopoietic stem cell transplant for non-malignant diseases, including inherited immune deficiencies, bone marrow failure syndromes, metabolic diseases, and acquired aplastic anemia. He is involved in clinical research in allogeneic transplant for patients with immune deficiencies and lymphoma and in a number of clinical trials relating to supportive care in bone marrow transplant.
MEMBERSHIPS
American Society of Hematology
American Society of Pediatric Hematology/Oncology
American Society for Transplant and Cellular Therapy
European Bone Marrow Transplant Society
Positions
- Senior Physician, Pediatric Hemato-Oncology Division and Bone Marrow Transplant
Conditions and treatment
- hematopoietic stem cell transplant
- inherited immune deficiencies
- bone marrow failure syndrome
- metabolic diseases
- aplastic anemia
- allogeneic transplant
- bone marrow transplant
- lymphoma
Credentials
Education and Training
- Clinical Fellow Safra Children’s Hospital, Pediatric Hematology and Oncology
- Clinical Fellow, CHLA, Division of Hematology, Oncology, and BMT
- Chief Resident, CHLA, Department of Pediatrics
- Resident Physician, CHLA, Department of Pediatrics
- MD Sackler School of Medicine, Tel Aviv University
Board Certifications
- Pediatrics
- Pediatric Hematology/Oncology
Publications
Ollech A, Mashiah J, Lev A, Simon AJ, Somech R, Adam E, Barzilai A, Hagin D, Greenberger S.
Treatment options for DOCK8 deficiency-related severe dermatitis. J Dermatol. 2021 May 27. doi: 10.1111/1346-8138.15955. Epub ahead of print. PMID: 34043252.
Wittmann Dayagi, T.; Sherman, G.; Bielorai, B.; Adam, E.; Besser, M.J.; Shimoni, A.; Nagler, A.; Toren, A.; Jacoby, E.; Avigdor, A. (2021)
Characteristics and risk factors of infections following CD28- based CD19 CAR-T cells, Leukemia & Lymphoma, 62:7, 1692-1701, DOI: 10.1080/10428194.2021.1881506
Hutt D, Bielorai B, Baturov B, Z’orbinski I, Ilin N, Adam E, Itzhaki O, Besser MJ, Toren A, Jacoby E.
Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients. Transfus Apher Sci. 2020 Aug;59(4):102769. doi: 10.1016/j.transci.2020.102769. Epub 2020 Apr 25. PMID: 32414613.
Adam E., Jubran R., Weitzman S. (2018) Epidemiology and Clinical Manifestations of Langerhans Cell Histiocytosis in Children. In: Abla O., Janka G. (eds) Histiocytic Disorders. Springer, Cham.
Adam, E.; Kim, H N.; Gang, E. J.; Schnair, C.; Lee, S. et al. The PI3Kδ Inhibitor Idelalisib Inhibits.Homing in an in Vitro and in Vivo Model of B ALL. Cancers 2017, 9(9)
Adam E, Jubran R, Weitzman S. Epidemiology and clinical manifestations of LCH in children. In: Histiocytosis. Springer, August 2017.
Adam E, Church JA. Antibody Levels to Bordetella pertussis and Neisseria meningitidis in Immunodeficient Patients Receiving Immunoglobulin Replacement Therapy. Journal of Clinical Immunology.
2015; 35: 213-217.
Adam E, Wang L, Herrington C, Bliss D, Church JA. Synchronous HIV/AIDS-Related EBV-Associated Smooth Muscle Tumors in a 20-Year-Old Female. Pediatr Infect Dis J 2014; 33:1055–1056.
